TY - JOUR
T1 - High-dose recombinant interleukin-2 alone
T2 - A regimen with limited activity in the treatment of advanced renal cell carcinoma
AU - Abrams, Jeffrey S.
AU - Rayner, Anthony A.
AU - Wiernik, Peter H.
AU - Parkinson, David R.
AU - Eisenberger, Mario
AU - Aronson, Frederick R.
AU - Gucalp, Rasim
AU - Atkins, Michael B.
AU - Hawkins, Michael J.
N1 - Funding Information:
Received January 26, 1990; revised April 18, 1990; accepted April 26, 1990. Supported by Public Health Service contracts NO1CM-73702 and NO1CM-57734 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services. J. S. Abrams, M. Eisenberger, Division of Medical Oncology, University of Maryland Cancer Center, Baltimore, Md. ...-.-• A. A. Rayner, F. R. Aronson, University of California at San Francisco, San Francisco, Calif. P. H. Wiernik, R. Gucalp, Albert Einstein Cancer Center, New York, NY. D. R. Parkinson, M. B. Atkins, Tufts-New England Medical Center, Boston, Mass. M. J. Hawkins, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Md. *Correspondence to: Jeffrey S. Abrams, M.D., Division of Medical Oncology, University of Maryland Cancer Center, 22 S. Greene St., Baltimore, MD 21201.
PY - 1990/7/18
Y1 - 1990/7/18
N2 - Sixteen patients with metastatic renal cell carcinoma were treated with high-dose bolus recombinant interleukin-2 (rIL-2) alone at a dose and schedule identical to those that produced a 35% response rate among 72 patients in a trial reported by the Surgery Branch, National Cancer Institute (NCI), Bethesda, Md, in which rIL-2 plus lymphokine-activated killer (LAK) cells was used for the treatment of renal cell carcinoma. Patients received two 5-day cycles of 100,000 Cetus U/kg (600,000 IU/kg) of rIL-2 infused intravenously over 15 minutes every 8 hours; each treatment cycle was separated by 1 week. No objective responses were seen. The toxicity of rIL-2 given alone at these high doses was similar to that noted with high-dose rIL-2-LAK cell therapy. The lack of responses seen in this trial also differed from the 21% response rate observed by the NCI Surgery Branch, using rIL-2 alone at an identical schedule and dose in 56 patients with renal cell carcinoma. Only minor differences in such recognized prognostic variables as performance status, tumor burden, and rIL-2 dose intensity were noted between this study and other trials reported by the NCI Surgery Branch and by the IL-2-LAK Working Group. Our analysis indicates that, because of the smaller number of patients in our trial, not enough subjects were included with the ideal characteristics to attain the 21% response rate seen in the NCI study. However, the precise nature of these characteristics remains unclear. [J Natl Cancer Inst 82:1202-1206, 1990].
AB - Sixteen patients with metastatic renal cell carcinoma were treated with high-dose bolus recombinant interleukin-2 (rIL-2) alone at a dose and schedule identical to those that produced a 35% response rate among 72 patients in a trial reported by the Surgery Branch, National Cancer Institute (NCI), Bethesda, Md, in which rIL-2 plus lymphokine-activated killer (LAK) cells was used for the treatment of renal cell carcinoma. Patients received two 5-day cycles of 100,000 Cetus U/kg (600,000 IU/kg) of rIL-2 infused intravenously over 15 minutes every 8 hours; each treatment cycle was separated by 1 week. No objective responses were seen. The toxicity of rIL-2 given alone at these high doses was similar to that noted with high-dose rIL-2-LAK cell therapy. The lack of responses seen in this trial also differed from the 21% response rate observed by the NCI Surgery Branch, using rIL-2 alone at an identical schedule and dose in 56 patients with renal cell carcinoma. Only minor differences in such recognized prognostic variables as performance status, tumor burden, and rIL-2 dose intensity were noted between this study and other trials reported by the NCI Surgery Branch and by the IL-2-LAK Working Group. Our analysis indicates that, because of the smaller number of patients in our trial, not enough subjects were included with the ideal characteristics to attain the 21% response rate seen in the NCI study. However, the precise nature of these characteristics remains unclear. [J Natl Cancer Inst 82:1202-1206, 1990].
UR - http://www.scopus.com/inward/record.url?scp=0025345935&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025345935&partnerID=8YFLogxK
U2 - 10.1093/jnci/82.14.1202
DO - 10.1093/jnci/82.14.1202
M3 - Article
C2 - 2194036
AN - SCOPUS:0025345935
SN - 0027-8874
VL - 82
SP - 1202
EP - 1206
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 14
ER -